Table 1.
Patients clinicopathologic characteristics at baseline.
| Characteristic | HER2-0 (n = 304) | HER2-Low (n = 304) | P-Value |
|---|---|---|---|
| Age | |||
| Median (range)-yr. | 61 (34–84) | 60 (35–85) | 0.36 |
| Age <50 | 53 (17%) | 63 (21%) | 0.12 |
| Ethnicity | 0.58 | ||
| Ashkenazi Jews | 151 (52%) | 133 (47%) | |
| Sephardi Jews | 119 (40%) | 120 (43%) | |
| Arab | 5 (2%) | 6 (2%) | |
| Other | 17 (6%) | 23 (8%) | |
| Postmenopausal | 234 (80%) | 220 (76%) | 0.32 |
| Tumor size | 0.12 | ||
| ≤2 cm | 226 (74%) | 242 (80%) | |
| >2 cm | 78 (26%) | 61 (20%) | |
| Node negative | 257 (85%) | 245 (81%) | 0.23 |
| Grade | 0.83 | ||
| Low | 43 (18%) | 42 (16%) | |
| Intermediate | 154 (64%) | 174 (66%) | |
| High | 43 (18%) | 46 (18%) | |
| Proliferation Index –Ki67% < 20% | 150 (70%) | 161 (71%) | 0.36 |
| Histologic typea | 0.005 | ||
| IDC | 232 (76%) | 259 (86%) | |
| ILC | 51 (17%) | 25 (8%) | |
| Other | 21 (7%) | 19 (6%) | |
| Estrogen receptor intensity | 0.103 | ||
| Weak | 4 (1%) | 6 (2%) | |
| Intermediate | 76 (25%) | 55 (18%) | |
| Strong | 224 (74%) | 243 (80%) | |
| Progesterone receptor positive | 260 (86%) | 262 (86%) | 0.90 |
| Progesterone receptor intensity | 0.83 | ||
| Weak | 79 (30%) | 88 (33%) | |
| Intermediate | 79 (30%) | 80 (31%) | |
| Strong | 102 (40%) | 94 (36%) | |
| Lympho-vascular invasion present | 20 (7%) | 14 (5%) | 0.37 |
| Perineural invasion present | 15 (5%) | 12 (4%) | 0.69 |
| Oncotype DX recurrence score | |||
| ≤ 25 | 252(83%) | 245 (81%) | 0.52 |
| < 25 | 52 (17%) | 59 (19%) | |
| <10 | 57 (19%) | 55 (18%) | 0.76 |
| 11-25 | 195 (64%) | 190 (63%) |
Data were missing on: Ethnicity = 34, Menopausal status = 25, Tumor size = 1, nodal status = 3, histologic grade = 106, Ki67 = 167, histologic type = 1, Lympho vascular invasion = 23, PNI = 23, adjuvant chemotherapy = 5, adjuvant hormonal therapy = 21.
3 Intensity hormone receptor was defined as follows: Weak- 0 < ER/PR ≤ 1, Intermediate – 1 < ER/PR ≤ 2, Strong – ER/PR > 2.
a
IDC- Infiltrating Ductal Carcinoma: includes IDC only or IDC and DCIS (Ductal Carcinoma In Situ), Other histology included: Tubular, Medullary and Mucinous.